UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   FORM 10-Q/A

                                (Amendment No.1)

            QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended March 31, 2003              Commission File Number 0-16093

                               CONMED CORPORATION
           (Exact name of the registrant as specified in its charter)

                 New York                                        16-0977505
     (State or other jurisdiction of                          (I.R.S. Employer
     incorporation or organization)                          Identification No.)

    525 French Road, Utica, New York                                13502
(Address of principal executive offices)                         (Zip Code)

                                 (315) 797-8375
              (Registrant's telephone number, including area code)

      Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes |X| No |_|

      Indicate by check mark whether the registrant is an accelerated filer (as
defined in Exchange Act Rule 126-2).

Yes |X| No |_|

      The number of shares outstanding of registrant's common stock, as of April
28, 2003 is 28,943,210 shares.

CONMED CORPORATION TABLE OF CONTENTS FORM 10-Q/A Explanatory Note This Amendment No. 1 to CONMED Corporation's Quarterly Report on Form 10-Q/A includes unaudited restated consolidated condensed financial statements as of March 31, 2003 and for the three months ended March 31, 2003. The purpose of this restatement is to reflect in our results of operations for the three months ended March 31, 2003, the purchase price allocation of our March 10, 2003 purchase of Bionx Implants, Inc. The purchase price allocation, which we arrived at with the assistance of a third party valuation, resulted in a $7.9 million write-off of purchased in-process research and development assets. Information regarding the restatement is included in Note 1 to the consolidated condensed financial statements. The items amended in this 10-Q/A are Items 1, 2 and 4. PART I FINANCIAL INFORMATION Item Number Page Item 1. Financial Statements - Consolidated Condensed Statements of Income 1 - Consolidated Condensed Balance Sheets 2 - Consolidated Condensed Statements of Cash Flows 3 - Notes to Consolidated Condensed Financial Statements 4 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3. Quantitative and Qualitative Disclosures About Market Risk 29 Item 4. Controls and Procedures 29 PART II OTHER INFORMATION Item 6. Exhibits and Reports on Form 8-K 29 Signatures 30

PART I FINANCIAL INFORMATION Item 1. CONMED CORPORATION CONSOLIDATED CONDENSED STATEMENTS OF INCOME (in thousands except per share amounts) (unaudited) Three Months Ended ------------------ March 31, --------- Restated -------- 2002 2003 -------- --------- Net sales ................................ $113,205 $ 118,034 Cost of sales ............................ 54,104 56,378 -------- --------- Gross profit ............................. 59,101 61,656 Selling and administrative ............... 34,468 37,145 Research and development ................. 3,824 3,703 Write-off of purchased in-process research and development assets ............... -- 7,900 Other expense (income) ................... -- (7,492) -------- --------- 38,292 41,256 Income from operations ................... 20,809 20,400 Interest expense ......................... 6,628 5,538 -------- --------- Income before income taxes ............... 14,181 14,862 Provision for income taxes ............... 5,105 8,194 -------- --------- Net income ............................... $ 9,076 $ 6,668 ======== ========= Per share data: Net income Basic ................................ $ .36 $ .23 Diluted .............................. .35 .23 Weighted average common shares* Basic ................................ 25,397 28,876 Diluted .............................. 25,969 29,037 * Not restated. See notes to consolidated condensed financial statements. 1

CONMED CORPORATION CONSOLIDATED CONDENSED BALANCE SHEETS (in thousands except share amounts) (unaudited) Restated -------- December 31, March 31, 2002 2003 ---- ---- ASSETS Current assets: Cash and cash equivalents ..................... $ 5,626 $ 6,250 Accounts receivable, net ...................... 58,093 60,257 Inventories ................................... 120,443 125,922 Deferred income taxes ......................... 6,304 6,321 Prepaid expenses and other current assets ..... 3,200 3,645 --------- --------- Total current assets ........................ 193,666 202,395 --------- --------- Property, plant and equipment, net .............. 95,608 97,403 Goodwill ........................................ 262,394 286,484 Other intangible assets, net .................... 180,271 194,631 Other assets .................................... 10,201 9,977 --------- --------- Total assets ................................ $ 742,140 $ 790,890 ========= ========= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of long-term debt ............. $ 2,631 $ 2,387 Accounts payable .............................. 22,074 21,851 Accrued compensation .......................... 10,463 9,484 Income taxes payable .......................... 5,885 8,260 Accrued interest .............................. 3,794 1,058 Other current liabilities ..................... 13,127 15,032 --------- --------- Total current liabilities ................... 57,974 58,072 --------- --------- Long-term debt .................................. 254,756 282,949 Deferred income taxes ........................... 28,446 38,426 Other long-term liabilities ..................... 14,025 14,347 --------- --------- Total liabilities ........................... 355,201 393,794 --------- --------- Shareholders' equity: Preferred stock, par value $.01 per share; authorized 500,000 shares; none outstanding . -- -- Common stock, par value $.01 per share; 100,000,000 shares authorized; 28,808,105 and 28,915,707 shares issued and outstanding in 2002 and 2003, respectively ............... 288 290 Paid-in capital ............................... 231,832 233,613 Retained earnings ............................. 162,391 169,059 Accumulated other comprehensive loss .......... (7,153) (5,447) Less 37,500 shares of common stock in treasury, at cost ..................................... (419) (419) --------- --------- Total shareholders' equity .................. 386,939 397,096 --------- --------- Total liabilities and shareholders equity . $ 742,140 $ 790,890 ========= ========= See notes to consolidated condensed financial statements. 2

CONMED CORPORATION CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) Three Months Ended ------------------ March 31, --------- Restated -------- 2002 2003 ---- ---- Cash flows from operating activities: Net income ........................................... $ 9,076 $ 6,668 -------- -------- Adjustments to reconcile net income to net cash provided by operations: Depreciation ................................... 2,206 2,374 Amortization ................................... 3,197 3,168 Deferred income taxes .......................... 2,758 4,409 Write-off of purchased in-process research and development assets ......................... -- 7,900 Increase (decrease) in cash flows from changes in assets and liabilities: Accounts receivable .................. 289 1,270 Inventories .......................... (3,605) (3,107) Accounts payable ..................... 6,503 (1,580) Income taxes payable ................. (167) 2,375 Accrued compensation ................. (2,607) (1,943) Accrued interest ..................... (3,381) (2,736) Other assets/liabilities, net ........ (1,918) 1,680 -------- -------- 3,275 13,810 -------- -------- Net cash provided by operating activities ...... 12,351 20,478 -------- -------- Cash flows from investing activities: Payments related to business acquisitions, net of cash acquired ........................... -- (48,177) Purchases of property, plant, and equipment ........ (3,208) (1,710) -------- -------- Net cash used by investing activities .......... (3,208) (49,887) -------- -------- Cash flows from financing activities: Net proceeds from exercise of stock options .......... 1,985 808 Payments on debt ..................................... (9,938) (3,051) Proceeds of debt ..................................... -- 31,000 -------- -------- Net cash provided (used) by financing activities (7,953) 28,757 -------- -------- Effect of exchange rate changes on cash and cash equivalents ....................... 42 1,276 -------- -------- Net increase in cash and cash equivalents .............. 1,232 624 Cash and cash equivalents at beginning of period ....... 1,402 5,626 -------- -------- Cash and cash equivalents at end of period ............. $ 2,634 $ 6,250 ======== ======== See notes to consolidated condensed financial statements. 3

CONMED CORPORATION NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (in thousands except share amounts) (unaudited) Note 1 - Operations and Significant Accounting Policies Organization and Operations The consolidated condensed financial statements include the accounts of CONMED Corporation and its subsidiaries ("CONMED", the "Company", "we" or "us"). All intercompany accounts and transactions have been eliminated. CONMED Corporation is a medical technology company specializing in instruments, implants and video equipment for arthroscopic sports medicine and powered surgical instruments, such as drills and saws, for orthopedic, ENT, neuro-surgery and other surgical specialties. We are a leading developer, manufacturer and supplier of RF electrosurgery systems used routinely to cut and cauterize tissue in nearly all types of surgical procedures worldwide, endoscopy products such as trocars, clip appliers, scissors and surgical staplers, and a full line of ECG electrodes for heart monitoring and other patient care products. We also offer integrated operating room systems and intensive care unit service managers. Our products are used in a variety of clinical settings, such as operating rooms, surgery centers, physicians' offices and critical care areas of hospitals. Our business is organized, managed and internally reported as a single segment, since our product offerings have similar economic, operating and other related characteristics. Restatement The purpose of the restatement described below is to reflect in our consolidated condensed financial statements for the quarter ended March 31, 2003, the purchase price allocation of our March 10, 2003 acquisition of Bionx Implants, Inc. (the "Bionx acquisition"). The purchase price allocation was arrived at with the assistance of a third party valuation. The impact of the restatement on the consolidated condensed statement of income for the quarter ended March 31, 2003, is to recognize expense of $7.9 million to write-off the purchased in-process research and development assets acquired as a result of the Bionx acquisition. No benefit for income taxes has been recorded on the write-off of the purchased in-process research and development assets as these costs are not deductible for income tax purposes. A summary of the impact of the restatement on the consolidated condensed statement of income for the three months ended March 31, 2003 is as follows: As Previously As Reported Adjustment Restated -------- ---------- -------- Consolidated Condensed Statement of Income Data For the Quarter Ended March 31, 2003: Write-off of purchased in-process Research and development assets ............. $ -- $ 7,900 $ 7,900 Income from operations ........................ 28,300 (7,900) 20,400 Income before income taxes .................... 22,762 (7,900) 14,862 Net income .................................... $14,568 $(7,900) $ 6,668 Net income per share: Basic ................................ $ .50 $ (.27) $ .23 Diluted .............................. .50 (.27) .23 4

The impact of the restatement on the consolidated condensed balance sheets, apart from the in-process research and development write-off, is the reclassification of a portion of the purchase price from goodwill to inventory, property, plant and equipment and other intangible assets as shown above. We have also recognized a deferred income tax liability based on the difference between the financial statement and tax basis of assets and liabilities acquired as a result of the Bionx acquisition. A summary of the impact of the restatement on the consolidated condensed balance sheet at March 31, 2003 is as follows: As Previously As Reported Adjustment Restated -------- ---------- -------- Consolidated Condensed Balance Sheet Data As of March 31, 2003: Inventories ............................. $125,721 $ 201 $125,922 Property, plant and equipment, net ...... 96,326 1,077 97,403 Goodwill ................................ 304,530 (18,046) 286,484 Other intangible assets, net ............ 180,209 14,422 194,631 Total assets ............................ $793,236 $ (2,346) $790,890 Deferred income taxes ................... $ 32,872 $ 5,554 $ 38,426 Total liabilities ....................... $388,240 $ 5,554 $393,794 Retained earnings ....................... $176,959 $ (7,900) $169,059 Total shareholders' equity .............. $404,996 $ (7,900) $397,096 The impact of the restatement on the consolidated condensed statement of cash flows is to reduce net income by the $7.9 million write-off of the purchased in-process research and development assets and increase non-cash expense related to the write-off by $7.9 million. The restatement had no effect on net cash provided by operating activities for the three months ended March 31, 2003. A summary of the impact of the restatement on the consolidated condensed statement of cash flows for the three months ended March 31, 2003 is as follows: As Previously As Reported Adjustment Restated -------- ---------- -------- Consolidated Condensed Statement of Cash Flows Data as of March 31, 2003: Net income ................................... $14,568 $(7,900) $ 6,668 Write-off of purchased in-process research and development assets ............ $ -- $ 7,900 $ 7,900 Net cash provided by operating activities .... $20,478 $ -- $20,478 The Bionx acquisition and the related purchased in-process research and development write-off are described more fully in Note 6 to the consolidated condensed financial statements. Stock-based Compensation We account for our stock-based compensation plans under the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees". No compensation expense has been recognized in the accompanying financial statements relative to our stock option plans. Pro forma information regarding net income and earnings per share is required by Statement of Financial Accounting Standards No. 123, 5

"Accounting for Stock-Based Compensation" ("SFAS 123") and has been determined as if we had accounted for our employee stock options under the fair value method of that statement. The weighted average fair value of options granted in the three months ended March 31, 2002 and 2003 was $8.66 and $6.56, respectively. The fair value of these options was estimated at the date of grant using a Black-Scholes options pricing model with the following weighted-average assumptions for options granted in the three months ended March 31, 2002 and 2003, respectively: Risk-free interest rates of 2.70% and 2.87%; volatility factors of the expected market price of the Company's common stock of 41.10% and 43.23%; a weighted-average expected life of the option of five years; and that no dividends would be paid on common stock. For purposes of the pro forma disclosures, the estimated fair value of the options is amortized to expense over the options' vesting period. The Company's pro forma information follows: Three months ended March 31, Restated -------- 2002 2003 ---- ---- Net income -- as reported ............ $ 9,076 $ 6,668 --------- --------- Pro forma stock-based employee compensation expense, net of related income tax effect .................. (474) (524) --------- --------- Net income -- pro forma .............. $ 8,602 $ 6,144 ========= ========= EPS - as reported: Basic ............................ $ .36 $ .23 Diluted .......................... $ .35 $ .23 EPS - pro forma: Basic ............................ $ .34 $ .21 Diluted .......................... $ .33 $ .21 Note 2 - Interim financial information The statements for the three months ended March 31, 2002 and 2003 are unaudited; in our opinion such unaudited statements include all adjustments (which comprise only normal recurring accruals) necessary for a fair presentation of the results for such periods. The results of operations for the three months ended March 31, 2003 are not necessarily indicative of the results of operations to be expected for any other quarter nor for the year ending December 31, 2003. The consolidated condensed financial statements and notes thereto should be read in conjunction with the financial statements and notes for the year ended December 31, 2002 included in our Annual Report to the Securities and Exchange Commission on Form 10-K. 6

Note 3 - Other comprehensive income (loss) Comprehensive income (loss) consists of the following: Three months ended March 31, Restated -------- 2002 2003 ---- ---- Net income ................................. $9,076 $6,668 ------ ------ Other comprehensive income: Foreign currency translation adjustment ................. 36 1,313 Cash flow hedging (net of income taxes) .................. 480 393 ------ ------ Comprehensive income ..................... $9,592 $8,374 ====== ====== Accumulated other comprehensive income (loss) consists of the following: Accumulated Minimum Cumulative Cash Other Pension Translation Flow Comprehensive Liability Adjustments Hedges Income (loss) --------- ----------- ------ ------------- Balance, December 31, 2002 ..... $(5,086) $(1,159) $(908) $(7,153) Foreign currency translation adjustments .............. -- 1,313 -- 1,313 Cash flow hedging (net of income taxes) ............ -- -- 393 393 ------- ------- ----- ------- Balance, March 31, 2003 ........ $(5,086) $ 154 $(515) $(5,447) ======= ======= ===== ======= Note 4 - Inventories The components of inventory are as follows: December 31, March 31, Restated -------- 2002 2003 ---- ---- Raw materials ...................... $ 44,701 $ 43,041 Work-in-process .................... 12,869 14,357 Finished goods ..................... 62,873 68,524 -------- -------- Total .................. $120,443 $125,922 ======== ======== 7

Note 5 - Earnings per share Basic earnings per share (EPS) is computed based on the weighted average number of common shares outstanding for the period. Diluted EPS gives effect to all dilutive potential shares outstanding (i.e., options and warrants) during the period. The following is a reconciliation of the weighted average shares used in the calculation of basic and diluted EPS (in thousands): Three months ended March 31, 2002 2003 ---- ---- Shares used in the calculation of Basic EPS(weighted average shares outstanding) ...................... 25,397 28,876 Effect of dilutive potential securities ............................... 572 161 ------ ------ Shares used in the calculation of Diluted EPS ........................... 25,969 29,037 ====== ====== The shares used in the calculation of diluted EPS exclude warrants and options to purchase shares where the exercise price was greater than the average market price of common shares for the period. Such shares aggregated 351 and 2,395 for the three months ended March 31, 2002 and 2003, respectively. Note 6 - Business acquisitions On January 13, 2003, we entered into an agreement to acquire the common stock of Bionx Implants, Inc. (the "Bionx acquisition") in a cash transaction valuing Bionx at $4.35 per share. We completed the acquisition on March 10, 2003, paying $47.0 million in cash which we financed through borrowings under our revolving credit facility. The results of Bionx's operations have been included in the financial statements since that date. Bionx develops and manufactures self-reinforced resorbable polymer implants including screws, pins and meniscal implants for use in a variety of orthopedic applications, including sports medicine and fracture fixation. In 2002, Bionx recorded revenues of approximately $18.0 million. The acquired product lines are expected to complement CONMED's existing orthopedic product lines. Pro forma statements of income for the three months ended March 31, 2002 and 2003, assuming the Bionx acquisition occurred as of January 1, 2002 are presented below. The pro forma net income and earnings per share for each period presented exclude the $7.9 million write-off of purchased in-process research and development assets discussed below. Three months ended March 31, 2002 2003 ---- ---- Net sales .................... $ 117,971 $ 121,716 Net income ................... $ 8,731 $ 14,004 Basic EPS .................... $ .34 $ .48 Diluted EPS .................. .34 .48 8

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition based on a third-party valuation. Goodwill and identifiable intangible assets associated with the Bionx acquisition are not deductible for income tax purposes. Restated -------- Cash................................................. $ 517 Other current assets................................. 7,284 Property, plant and equipment........................ 2,459 In-process research and development.................. 7,900 Identifiable intangible assets....................... 15,700 Goodwill............................................. 22,351 ------- Total assets acquired................................ 56,211 ------- Current liabilities.................................. (3,120) Deferred income taxes................................ (5,554) Other long-term liabilities.......................... (521) ------- Total liabilities assumed............................ (9,195) ------- Net assets acquired.................................. $47,016 ======= Based on the third-party valuation, $7.9 million of the purchase price represents the estimated fair value of projects that, as of the acquisition date had not reached technological feasibility and had no alternative future use. Accordingly, this amount of purchased in-process research and development assets was written-off to other expense in accordance with FASB Interpretation No. 4, "Applicability of FASB Statement No. 2 to Business Combinations Accounted for by the Purchase Method". No benefit for income taxes has been recorded on the write-off of purchased in-process research and development assets as these costs are not deductible for income tax purposes. The purchased in-process research and development value relates to next generation sports medicine and orthopedic products, which are expected to be released between the second quarter of 2003 and fourth quarter of 2004. The acquired projects include enhancements and upgrades to existing device technology, introduction of new device functionality and the development of new materials technology for sports medicine and orthopedic applications. The value of the in-process research and development was calculated using a discounted cash flow analysis of the anticipated net cash flow stream associated with the in-process technology of the related product sales. The estimated net cash flows were discounted using a discount rate of 22%, which was based on the weighted-average cost of capital for publicly-traded companies within the medical device industry and adjusted for the stage of completion of each of the in-process research and development projects. The risk and return considerations surrounding the stage of completion were based on costs, man-hours and complexity of the work completed versus to be completed and other risks associated with achieving technological feasibility. In total, these projects were approximately 40% complete as of the acquisition date. The total budgeted costs for the projects were approximately $5.5 million and the remaining costs to complete these projects were approximately $3.3 million as of the acquisition date. The major risks and uncertainties associated with the timely and successful completion of these projects consist of the ability to confirm the safety and efficacy of the technologies and products based on the data from clinical trials and obtaining the necessary regulatory approvals. In addition, no assurance can be given that the underlying assumptions used to forecast the cash flows or the timely and successful completion of such projects will materialize, as estimated. For these reasons, among others, actual results may vary significantly from the estimated results. 9

Of the $15.7 million of acquired intangible assets, $.8 million were assigned to registered trademarks and are not subject to amortization. The remaining $14.9 million of acquired intangible assets have a weighted average useful life of 20 years. The intangible assets that make up that amount include $9.0 million of customer relationships (38 year weighted average useful life), $5.4 million of core technology (12 year weighted average useful life) and $.5 million of distributor relationships (7 year weighted average useful life). During the quarter ended March 31, 2003, we paid additional purchase consideration related to the December 31, 2002 acquisition of CORE Dynamics, Inc. (the "CORE acquisition") of approximately $1.7 million which resulted in an increase to goodwill and which had been contingent on the satisfactory execution of the plan to transition manufacturing and distribution from CORE's Jacksonville, Florida facility to our facilities in Utica, New York. During the quarter ended March 31, 2003, we incurred approximately $1.7 million in other acquisition expenses related primarily to the CORE and Bionx acquisitions of which $1.3 million has been recorded in other expense and $.4 million has been recorded to cost of sales. The $1.3 million recorded to other expense consists of various acquisition integration costs to wind down CORE operations in Jacksonville, Florida and Bionx operations in Blue Bell, Pennsylvania. The $.4 million recorded to cost of sales consists of the step-up to fair value related to the sale of a portion of the inventory acquired as a result of the CORE and Bionx acquisitions as well as certain training and transition-related costs related to the transfer of CORE's manufacturing operations. Note 7 - Other expense (income) Other expense (income) consists of the following: Gain on settlement of a contractual dispute, net of legal costs................................... ($9,000) Acquisition-related costs..................................... 1,342 Loss on early extinguishments of debt......................... 166 ------- Other expense (income)............................... $(7,492) ======= On March 10, 2003, we entered into an agreement with Bristol-Myers Squibb Company ("BMS") and Zimmer, Inc., ("Zimmer") to settle a contractual dispute related to the 1997 sale by BMS and its then subsidiary, Zimmer, of Linvatec Corporation to CONMED Corporation. As a result of the agreement, BMS paid us $9.5 million in cash, which has been recorded as a gain on settlement of a contractual dispute net of $.5 million in legal costs. During the quarter ended March 31, 2003, we incurred approximately $1.7 million in costs related primarily to the CORE acquisition and the Bionx acquisition of which $1.3 million has been recorded in other expense as discussed in Note 6 to the consolidated condensed financial statements. During the quarter ended March 31, 2003 we purchased $2.6 million of our 9% senior subordinated notes and recorded expense of $.2 million in premium and unamortized deferred financing costs to other expense related to this purchase. 10

Note 8 - Goodwill and other intangible assets The changes in the net carrying amount of goodwill for the three months ended March 31, 2003 are as follows: Restated -------- Balance as of January 1, 2003................................... $ 262,394 Goodwill acquired .............................................. 24,090 --------- Balance as of March 31, 2003.................................... $ 286,484 ========= Other intangible assets consist of the following: December 31, 2002 March 31, 2003 ----------------- -------------- Gross Gross Carrying Accumulated Carrying Accumulated Amortized intangible assets: Amount Amortization Amount Amortization ------ ------------ ------ ------------ Restated -------- Customer relationships............................... $ 96,712 $(12,725) $ 105,712 $(13,362) Patents and other intangible assets.................. 23,674 (13,534) 29,327 (13,990) Unamortized intangible assets: Trademarks and tradenames............................ 86,144 -- 86,944 -- -------- -------- -------- -------- $206,530 $(26,259) $221,983 $(27,352) ======== ======== ======== ======== Other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. The weighted average amortization period for intangible assets which are amortized is 22 years. Customer relationships are being amortized over 38 years. Patents and other intangible assets are being amortized over a weighted average life of 9 years. The trademarks and tradenames intangible asset has been determined to have an indefinite life and therefore is not amortized. Amortization expense related to intangible assets which are subject to amortization totaled $1,352 in the three months ended March 31, 2003 and $1,789 in the three months ended March 31, 2002 and is included in selling and administrative expense on the consolidated condensed statement of income. The estimated amortization expense for the year ending December 31, 2003 and for each of the five succeeding years is as follows: Restated -------- 2003 $5,978 2004 5,579 2005 4,776 2006 4,366 2007 4,143 2008 3,934 Note 9 -- Guarantees We provide service and warranty policies on certain of our products at the time of sale. Liability under service and warranty policies is based upon a review of historical warranty and service claim experience. Adjustments are made to accruals as claim data and historical experience warrant. 11

The changes in the carrying amount of service and product warranties for the three months ended March 31, 2003 are as follows: Balance as of January 1, 2003........................ $ 3,213 Provision for warranties............................. 1,211 Claims made.......................................... (1,100) ------- Balance as of March 31, 2003 $ 3,324 ======= Note 10 - New Accounting Pronouncements In April 2002, the FASB issued SFAS No. 145, "Rescission of FASB Statements No. 4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections," which updates, clarifies, and simplifies certain existing accounting pronouncements beginning at various dates in 2002 and 2003. This Statement rescinds SFAS 4 and SFAS 64, which required net gains or losses from the extinguishment of debt to be classified as an extraordinary item in the income statement. These gains and losses will now be classified as extraordinary only if they meet the criteria for such classification as outlined in Accounting Principles Board ("APB") Opinion 30, which allows for extraordinary treatment if the item is material and both unusual and infrequent in nature. We adopted this pronouncement during 2003. As a result we will reclassify the extraordinary loss recognized in the third quarter of 2002 related to the refinancing of debt to ordinary income in the 2003 annual and interim financial statements. In July 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated with Exit or Disposal Activities," which addresses financial accounting and reporting for costs associated with exit or disposal activities. This Statement supersedes Emerging Issues Task Force Issue No. 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit and Activity (including Certain Costs Incurred in a Restructuring)." The provisions of this Statement are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. This pronouncement has not had an impact on our financial condition or results of operations during 2003. In November 2002, FASB Interpretation ("FIN") No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others" was issued. The interpretation provides guidance on the guarantor's accounting and disclosure requirements for guarantees, including indirect guarantees of indebtedness of others. We have adopted the disclosure requirements of the interpretation as of December 31, 2002. The accounting guidelines are applicable to guarantees issued after December 31, 2002 and require that we record a liability for the fair value of such guarantees in the balance sheet. FIN 45 has not had a material accounting impact on our financial condition or results of operations during 2003. In January 2003, FIN No. 46, "Consolidation of Variable Interest Entities" was issued. The interpretation provides guidance on consolidating variable interest entities and applies immediately to variable interests created after January 31, 2003. The guidelines of the interpretation will become applicable for us in our third quarter 2003 financial statements for variable interest entities created before February 1, 2003. The interpretation requires variable interest entities to be consolidated if the equity investment at risk is not sufficient to permit an entity to finance its activities without support from other parties or the equity investors lack certain specified characteristics. We are reviewing FIN No. 46 to determine its impact, if any, on future reporting periods, and do not currently anticipate any material accounting or disclosure requirement under the provisions of the interpretation. In April 2003, FAS No. 149 "Amendment of Statement 133 on Derivative Instruments and Hedging Activities" was issued. FAS No. 149 amends and clarifies financial accounting 12

and reporting for derivative instruments embedded in other contracts and for hedging activities under FAS No. 133, "Accounting for Derivative Instruments and Hedging Activities". FAS No. 149 will be applicable for us in our third quarter 2003. We are reviewing FAS No. 149 to determine its impact, if any, on future reporting periods, and do not currently anticipate any material accounting or disclosure requirement under the provisions of the statement. Note 11 - Guarantor financial statements Our senior credit agreement and Senior Subordinated Notes (the "Notes") are guaranteed (the "Subsidiary Guarantees") by each of our subsidiaries (the "Subsidiary Guarantors") except CONMED Receivables Corporation (the "Non-Guarantor Subsidiary"). The Subsidiary Guarantees provide that each Subsidiary Guarantor will fully and unconditionally guarantee our obligations under our senior credit agreement and the Notes on a joint and several basis. Each Subsidiary Guarantor and Non-Guarantor Subsidiary is wholly-owned by CONMED Corporation. The following supplemental financial information sets forth on a condensed consolidating basis, condensed consolidating balance sheets, statements of income and statements of cash flows for the Parent Company only, Subsidiary Guarantors and Non-Guarantor Subsidiary and for the Company as of December 31, 2002 and March 31, 2003 and for the three months ended March 31, 2002 and 2003. 13

CONMED CORPORATION CONSOLIDATING CONDENSED BALANCE SHEET December 31, 2002 (in thousands) Parent Non- Company Subsidiary Guarantor Company Only Guarantors Subsidiary Eliminations Total ---- ---------- ---------- ------------ ----- ASSETS Current assets: Cash and cash equivalents ............... $ 3,824 $ 1,516 $ 286 $ -- $ 5,626 Accounts receivable, net ................ 746 13,397 43,950 -- 58,093 Inventories ............................. 25,829 94,614 -- -- 120,443 Deferred income taxes ................... 6,210 -- 94 -- 6,304 Prepaid expenses and other current assets 823 2,377 -- -- 3,200 --------- --------- ------- --------- --------- Total current assets .............. 37,432 111,904 44,330 -- 193,666 --------- --------- ------- --------- --------- Property, plant and equipment, net .......... 47,327 48,281 -- -- 95,608 Goodwill, net ............................... 96,393 166,001 -- -- 262,394 Other intangible assets, net ................ 3,565 176,706 -- -- 180,271 Other assets ................................ 498,111 2,406 -- (490,316) 10,201 --------- --------- ------- --------- --------- Total assets ............................ $ 682,828 $ 505,298 $44,330 $(490,316) $ 742,140 ========= ========= ======= ========= ========= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of long-term debt ....... $ 1,284 $ 1,347 $ -- $ -- $ 2,631 Accounts payable ........................ 4,907 17,167 -- -- 22,074 Accrued compensation .................... 4,052 6,411 -- -- 10,463 Income taxes payable .................... 5,885 -- -- -- 5,885 Accrued interest ........................ 3,733 36 25 -- 3,794 Other current liabilities ............... 5,781 7,346 -- -- 13,127 --------- --------- ------- --------- --------- Total current liabilities ........... 25,642 32,307 25 -- 57,974 --------- --------- ------- --------- --------- Long-term debt .............................. 234,468 20,288 -- 254,756 Deferred income taxes ....................... 28,446 -- -- 28,446 Other long-term liabilities ................. 7,333 269,259 41,932 (304,499) 14,025 --------- --------- ------- --------- --------- Total liabilities ....................... 295,889 321,854 41,957 (304,499) 355,201 --------- --------- ------- --------- --------- Shareholders' equity: Preferred stock ......................... -- -- -- -- -- Common stock ............................ 288 -- -- -- 288 Paid-in capital ......................... 231,832 -- 2,000 (2,000) 231,832 Retained earnings ....................... 162,391 184,603 373 (184,976) 162,391 Accumulated other comprehensive loss .... (7,153) (1,159) -- 1,159 (7,153) Less common stock in treasury, at cost .. (419) -- -- -- (419) --------- --------- ------- --------- --------- Total shareholders' equity .......... 386,939 183,444 2,373 (185,817) 386,939 --------- --------- ------- --------- --------- Total liabilities and shareholders' equity $ 682,828 $ 505,298 $44,330 $(490,316) $ 742,140 ========= ========= ======= ========= ========= 14

CONMED CORPORATION CONSOLIDATING CONDENSED BALANCE SHEET Restated March 31, 2003 (in thousands)(unaudited) Parent Non- Company Subsidiary Guarantor Company Only Guarantors Subsidiary Eliminations Total ---- ---------- ---------- ------------ ----- ASSETS Current assets: Cash and cash equivalents ....... $ 4,174 $ 1,791 $ 285 $ -- $ 6,250 Accounts receivable, net ........ -- 16,607 43,650 -- 60,257 Inventories ..................... 27,073 98,849 -- -- 125,922 Deferred income taxes ........... 6,227 -- 94 -- 6,321 Prepaid expenses and other current assets .............. 914 2,731 -- -- 3,645 --------- -------- ------- --------- --------- Total current assets ...... 38,388 119,978 44,029 -- 202,395 --------- -------- ------- --------- --------- Property, plant and equipment, net .. 47,375 50,028 -- -- 97,403 Goodwill, net ....................... 98,095 188,389 -- -- 286,484 Other intangible assets, net ........ 3,533 191,098 -- -- 194,631 Other assets ........................ 540,928 2,431 -- (533,382) 9,977 --------- -------- ------- --------- --------- Total assets .................... $ 728,319 $551,924 $44,029 $(533,382) $ 790,890 ========= ======== ======= ========= ========= LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of long-term debt $ 1,034 $ 1,353 $ -- $ -- $ 2,387 Accounts payable ................ 4,478 17,373 -- -- 21,851 Accrued compensation ............ 3,264 6,220 -- -- 9,484 Income taxes payable ............ 8,260 -- -- -- 8,260 Accrued interest ................ 797 236 25 -- 1,058 Other current liabilities ....... 4,848 10,184 -- -- 15,032 --------- -------- ------- --------- --------- Total current liabilities ... 22,681 35,366 25 -- 58,072 --------- -------- ------- --------- --------- Long-term debt ...................... 262,574 20,375 -- 282,949 Deferred income taxes ............... 38,426 -- -- 38,426 Other long-term liabilities ......... 7,542 313,087 41,613 (347,895) 14,347 --------- -------- ------- --------- --------- Total liabilities ............... 331,223 368,828 41,638 (347,895) 393,794 --------- -------- ------- --------- --------- Shareholders' equity: Preferred stock ................. -- -- -- -- -- Common stock .................... 290 -- -- -- 290 Paid-in capital ................. 233,613 -- 2,000 (2,000) 233,613 Retained earnings ............... 169,059 182,942 391 (183,333) 169,059 Accumulated other comprehensive income (loss) ............... (5,447) 154 -- (154) (5,447) Less common stock in treasury, at cost .............. (419) -- -- -- (419) --------- -------- ------- --------- --------- Total shareholders' equity .. 397,096 183,096 2,391 (185,487) 397,096 --------- -------- ------- --------- --------- Total liabilities and shareholders' equity ...... $ 728,319 $551,924 $44,029 $(533,382) $ 790,890 ========= ======== ======= ========= ========= 15

CONMED CORPORATION CONSOLIDATING CONDENSED STATEMENT OF INCOME Three Months Ended March 31, 2002 (in thousands) (unaudited) Parent Company Subsidiary Non-Guarantor Company Only Guarantors Subsidiary Eliminations Total ---- ---------- ---------- ------------ ----- Net sales ..................... $26,299 $ 86,906 $ -- $ -- $113,205 Cost of sales ................. 14,003 40,101 -- -- 54,104 ------- -------- ----- -------- -------- Gross profit .................. 12,296 46,805 -- -- 59,101 Selling and administrative .... 7,447 27,355 (334) -- 34,468 Research and development ...... 429 3,395 -- -- 3,824 ------- -------- ----- -------- -------- 7,876 30,750 (334) -- 38,292 ------- -------- ----- -------- -------- Income from operations ........ 4,420 16,055 334 -- 20,809 Interest expense .............. -- 6,308 320 -- 6,628 ------- -------- ----- -------- -------- Income before income taxes .... 4,420 9,747 14 -- 14,181 Provision for income taxes .... 1,591 3,509 5 -- 5,105 ------- -------- ----- -------- -------- Income before equity in earnings of unconsolidated subsidiaries .............. 2,829 6,238 9 -- 9,076 Equity in earnings of unconsolidated subsidiaries 6,247 -- -- (6,247) -- ------- -------- ----- -------- -------- Net income .................... $ 9,076 $ 6,238 $ 9 $ (6,247) $ 9,076 ======= ======== ===== ======== ======== 16

CONMED CORPORATION CONSOLIDATING CONDENSED STATEMENT OF INCOME Restated Three Months Ended March 31, 2003 (in thousands) (unaudited) Parent Company Subsidiary Non-Guarantor Company Only Guarantors Subsidiary Eliminations Total ---- ---------- ---------- ------------ ----- Net sales ..................... $ 29,135 $ 88,899 $ -- $ -- $ 118,034 Cost of sales ................. 16,058 40,320 -- -- 56,378 -------- -------- ----- ------- --------- Gross profit .................. 13,077 48,579 -- -- 61,656 Selling and administrative .... 7,933 29,455 (243) -- 37,145 Research and development ...... 481 3,222 -- -- 3,703 Write-off of purchased in-process research and development assets ...... -- 7,900 -- -- 7,900 Other expense (income) ........ (8,324) 832 -- -- (7,492) -------- -------- ----- ------- --------- 90 41,409 (243) -- 41,256 -------- -------- ----- ------- --------- Income from operations ........ 12,987 7,170 243 -- 20,400 Interest expense .............. -- 5,322 216 -- 5,538 -------- -------- ----- ------- --------- Income before income taxes .... 12,987 1,848 27 -- 14,862 Provision for income taxes .... 4,676 3,509 9 -- 8,194 -------- -------- ----- ------- --------- Income (loss) before equity in earnings of unconsolidated subsidiaries .............. 8,311 (1,661) 18 -- 6,668 Equity in earnings (loss) of unconsolidated subsidiaries (1,643) -- -- 1,643 -- -------- -------- ----- ------- --------- Net income (loss) ............. $ 6,668 $ (1,661) $ 18 $ 1,643 $ 6,668 ======== ======== ===== ======= ========= 17

CONMED CORPORATION CONSOLIDATING CONDENSED STATEMENT OF CASH FLOWS Three Months Ended March 31, 2002 (in thousands) (unaudited) Parent Non- Company Subsidiary Guarantor Company Only Guarantors Subsidiary Eliminations Total ---- ---------- ---------- ------------ ----- Net cash flows from operating activities ........................ $ 2,761 $ 6,090 $ 3,500 $ -- $ 12,351 ------- ------- ------- ------- -------- Cash flows from investing activities: Distributions from subsidiaries ... 6,752 -- -- (6,752) -- Purchases of property, plant and equipment ..................... (1,560) (1,648) -- -- (3,208) ------- ------- ------- ------- -------- Net cash provided (used) by investing activities ... 5,192 (1,648) -- (6,752) (3,208) ------- ------- ------- ------- -------- Cash flows from financing: Distributions to parent ........... -- (4,114) -- 4,114 -- Repayment on note payable to parent -- -- (2,638) 2,638 -- Net proceeds from exercise of stock options ................... 1,985 -- -- -- 1,985 Payments on debt .................. (9,938) -- -- -- (9,938) ------- ------- ------- ------- -------- Net cash provided (used) by financing activities ..... (7,953) (4,114) (2,638) 6,752 (7,953) ------- ------- ------- ------- -------- Effect of exchange rate changes on cash and cash equivalents .............. -- 42 -- -- 42 ------- ------- ------- ------- -------- Net increase (decrease) in cash and cash equivalents .................. -- 370 862 -- 1,232 Cash and cash equivalents at beginning of period ............... -- 1,181 221 -- 1,402 ------- ------- ------- ------- -------- Cash and cash equivalents at end of period ..................... $ -- $ 1,551 $ 1,083 $ -- $ 2,634 ======= ======= ======= ======= ======== 18

CONMED CORPORATION CONSOLIDATING CONDENSED STATEMENT OF CASH FLOWS Three Months Ended March 31, 2003 (in thousands) (unaudited) Parent Non- Company Subsidiary Guarantor Company Only Guarantors Subsidiary Eliminations Total ---- ---------- ---------- ------------ ----- Net cash provided by operating activities $ 11,059 $ 9,101 $ 318 $ -- $ 20,478 -------- -------- ----- -------- -------- Cash flows from investing activities: Distributions to subsidiaries ....... (36,881) -- -- 36,881 -- Payments related to business acquisitions, net of cash acquired (1,678) (46,499) -- -- (48,177) Purchases of property, plant and equipment ....................... (907) (803) -- -- (1,710) -------- -------- ----- -------- -------- Net cash provided (used) by investing activities ..... (39,466) (47,302) -- 36,881 (49,887) -------- -------- ----- -------- -------- Cash flows from financing: Net distributions to parent ......... -- 37,200 -- (37,200) -- Borrowings on note payable to parent -- -- (319) 319 -- Net proceeds from exercise of stock options ................... 808 -- -- -- 808 Payments on debt .................... (3,051) -- -- -- (3,051) Proceeds of debt .................... 31,000 -- -- -- 31,000 -------- -------- ----- -------- -------- Net cash provided (used) by financing activities ....... 28,757 37,200 (319) (36,881) 28,757 -------- -------- ----- -------- -------- Effect of exchange rate changes on cash and cash equivalents ................ -- 1,276 -- -- 1,276 -------- -------- ----- -------- -------- Net increase (decrease) in cash and cash equivalents .................. 350 275 (1) -- 624 Cash and cash equivalents at beginning of period ................ 3,824 1,516 286 -- 5,626 -------- -------- ----- -------- -------- Cash and cash equivalents at end of period ...................... $ 4,174 $ 1,791 $ 285 $ -- $ 6,250 ======== ======== ===== ======== ======== 19

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Forward-Looking Statements Made in this Form 10-Q/A In this Form 10-Q/A, we make forward-looking statements about our financial condition, results of operations and business. Forward-looking statements are statements made by us concerning events that may or may not occur in the future. These statements may be made directly in this document or may be "incorporated by reference" from other documents. You can find many of these statements by looking for words like "believes," "expects," "anticipates," "estimates" or similar expressions. Forward-Looking Statements are not Guarantees of Future Performance Forward-looking statements involve known and unknown risks, uncertainties and other factors, including those that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include those identified under "Risk Factors" in our Annual Report on Form 10-K for the year-ended December 31, 2002 and the following, among others: o general economic and business conditions; o cyclical customer purchasing patterns due to budgetary and other constraints; o changes in customer preferences; o competition; o changes in technology; o our ability to manufacture product consistently and in a timely manner, especially those products involving delicate or complex manufacturing processes; o the introduction and acceptance of new products, including our PowerPro(R)battery-powered instrument product line; o the success of our distribution arrangement with DePuy Orthopaedics; o the integration of any acquisition, including the Bionx acquisition; o changes in business strategy; o the possibility that United States or foreign regulatory and/or administrative agencies might initiate enforcement actions against us or our distributors; o our indebtedness; o quality of our management and business abilities and the judgment of our personnel; o the risk of litigation, especially patent litigation as well as the cost associated with patent and other litigation; o changes in regulatory requirements; and o the availability, terms and deployment of capital. See "Management's Discussion and Analysis of Financial Condition and Results of Operations" below and "Business" in our Annual Report on Form 10-K for the year-ended December 31, 2002 for a further discussion of these factors. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to publicly release any revisions to 20

these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q/A or to reflect the occurrence of unanticipated events. Restatement The purpose of the restatement described below is to reflect in our consolidated condensed financial statements for the quarter ended March 31, 2003, the purchase price allocation of our March 10, 2003 acquisition of Bionx Implants, Inc. (the "Bionx acquisition"). The purchase price allocation was arrived at with the assistance of a third party valuation. The impact of the restatement on the consolidated condensed statement of income for the quarter ended March 31, 2003, is to recognize expense of $7.9 million to write-off the purchased in-process research and development assets acquired as a result of the Bionx acquisition. No benefit for income taxes has been recorded on the write-off of the purchased in-process research and development assets as these costs are not deductible for income tax purposes. A summary of the impact of the restatement on the consolidated condensed statement of income for the three months ended March 31, 2003 is as follows: As Previously As Reported Adjustment Restated Consolidated Condensed Statement of Income Data For the Quarter Ended March 31, 2003: Write-off of purchased in-process research and development assets ............. $ -- $ 7,900 $ 7,900 Income from operations ........................ 28,300 (7,900) 20,400 Income before income taxes .................... 22,762 (7,900) 14,862 Net income .................................... $14,568 $(7,900) $ 6,668 Net income per share: Basic ................................ $ .50 $ (.27) $ .23 Diluted .............................. .50 (.27) .23 The impact of the restatement on the consolidated condensed balance sheets, apart from the in-process research and development write-off, is the reclassification of a portion of the purchase price from goodwill to inventory, property, plant and equipment and other intangible assets as shown above. We have also recognized a deferred income tax liability based on the difference between the financial statement and tax basis of assets and liabilities acquired as a result of the Bionx acquisition. A summary of the impact of the restatement on the consolidated condensed balance sheet at March 31, 2003 is as follows: 21

As Previously As Reported Adjustment Restated -------- ---------- -------- Consolidated Condensed Balance Sheet Data As of March 31, 2003: Inventories ............................. $125,721 $ 201 $125,922 Property, plant and equipment, net ...... 96,326 1,077 97,403 Goodwill ................................ 304,530 (18,046) 286,484 Other intangible assets, net ............ 180,209 14,422 194,631 Total assets ............................ $793,236 (2,346) $790,890 Deferred income taxes ................... $ 32,872 $ 5,554 $ 38,426 Total liabilities ....................... $388,240 $ 5,554 $393,794 Retained earnings ....................... $176,959 $ (7,900) $169,059 Total shareholders' equity .............. $404,996 $ (7,900) $397,096 The impact of the restatement on the consolidated condensed statement of cash flows is to reduce net income by the $7.9 million write-off of the purchased in-process research and development assets and increase non-cash expense related to the write-off by $7.9 million. The restatement had no effect on net cash provided by operating activities for the three months ended March 31, 2003. A summary of the impact of the restatement on the consolidated condensed statement of cash flows for the three months ended March 31, 2003 is as follows: As Previously As Reported Adjustment Restated -------- ---------- -------- Consolidated Condensed Statement of Cash Flows Data as of March 31, 2003: Net income ................................... $14,568 $(7,900) $ 6,668 Write-off of purchased in-process research and development assets ............ -- 7,900 7,900 Net cash provided by operating activities .... $20,478 $ -- $20,478 The Bionx acquisition and the related purchased in-process research and development write-off are described more fully in Note 6 to the consolidated condensed financial statements. Critical Accounting Estimates Preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Note 1 to the consolidated financial statements in our Annual Report on Form 10K for the year-ended December 31, 2002 describes the significant accounting policies used in preparation of the consolidated financial statements. The most significant areas involving management judgments and estimates are described below and are considered by management to be critical to understanding the financial condition and results of operations of CONMED Corporation. 22

Revenue Recognition We recognize revenue upon shipment of product and passage of title to our customers. Factors considered in our revenue recognition policy are as follows: o Sales to customers are evidenced by firm purchase orders. Title and the risks and rewards of ownership are transferred to the customer when product is shipped. o Payment by the customer is due under fixed payment terms. Even when the sale is to a distributor, payment to us is not contractually or implicitly delayed until the product is resold by the distributor. o We place certain of our capital equipment with customers in return for commitments to purchase disposable products over time periods generally ranging from one to three years. In these circumstances, no revenue is recognized upon capital shipment and we recognize revenue upon the disposable product shipment. o Product returns are only accepted at the discretion of the Company and in keeping with our "Returned Goods Policy". Product returns have not been significant historically. We accrue for sales returns, rebates and allowances based upon analysis of historical data. o The terms of the Company's sales to customers do not involve any obligations for the Company to perform future services. Limited warranties are generally provided for capital equipment sales and provisions for warranty are provided at the time of product shipment. o Amounts billed to customers related to shipping and handling are included in net sales. Shipping and handling costs are included in selling and administrative expense. o We sell to a diversified base of customers around the world and, therefore, believe there is no material concentration of credit risk. o We assess the risk of loss on accounts receivable and adjust the allowance for doubtful accounts based on this risk assessment. Historically, losses on accounts receivable have not been material. Management believes the allowance for doubtful accounts of $1.0 million at March 31, 2003 is adequate to provide for any probable losses from accounts receivable. Business Acquisitions We completed the Bionx acquisition in 2003 with a purchase price of $47.0 million and have a history of growth through acquisitions. The assets and liabilities of acquired businesses are recorded under the purchase method at their estimated fair values at the dates of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. Other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. We have accumulated goodwill of $286.5 million and other intangible assets of $194.6 million at March 31, 2003. In accordance with Statement of Financial Accounting Standards ("SFAS") No. 142, "Goodwill and Other Intangible Assets," ("SFAS 142"), goodwill and intangible assets deemed to have indefinite lives are not amortized, but are subject to annual impairment testing. The identification and measurement of goodwill impairment involves the estimation of the fair value of our business. The estimates of fair value are based on the best information available as of the date of the assessment, which primarily incorporate management assumptions about expected future cash flows and contemplate 23

other valuation techniques. Future cash flows can be affected by changes in industry or market conditions or the rate and extent to which anticipated synergies or cost savings are realized with newly acquired entities. Intangible assets with a finite life are amortized over the estimated useful life of the asset. Intangible assets which continue to be subject to amortization are also evaluated on an annual basis to determine whether events and circumstances warrant a revision to the remaining period of amortization. An intangible asset is determined to be impaired when estimated future cash flows indicate the carrying amount of the asset may not be recoverable. Although no goodwill or other intangible asset impairment has been recorded to date, there can be no assurances that future impairment will not occur. In connection with the Bionx acquisition, significant estimates were made in the valuation of the purchased in-process research and development assets. The aggregate purchased in-process research and development value relates to next generation sports medicine and orthopedic products, which are expected to be released between the second quarter of 2003 and fourth quarter of 2004. The acquired projects include enhancements and upgrades to existing device technology, introduction of new device functionality and the development of new materials technology for sports medicine and orthopedic applications. The value of the in-process research and development was calculated using a discounted cash flow analysis of the anticipated net cash flow stream associated with the in-process technology of the related product sales. The estimated net cash flows were discounted using a discount rate of 22%, which was based on the weighted-average cost of capital for publicly-traded companies within the medical device industry and adjusted for the stage of completion of each of the in-process research and development projects. The risk and return considerations surrounding the stage of completion were based on costs, man-hours and complexity of the work completed versus to be completed and other risks associated with achieving technological feasibility. In total, these projects were approximately 40% complete as of the acquisition date. The total budgeted costs for the projects were approximately $5.5 million and the remaining costs to complete these projects were approximately $3.3 million as of the acquisition date. The major risks and uncertainties associated with the timely and successful completion of these projects consist of the ability to confirm the safety and efficacy of the technologies and products based on the data from clinical trials and obtaining the necessary regulatory approvals. In addition, no assurance can be given that the underlying assumptions used to forecast the cash flows or the timely and successful completion of such projects will materialize, as estimated. For these reasons, among others, actual results may vary significantly from the estimated results. Pension Plans We sponsor defined benefit pension plans for the Company and its subsidiaries. Major assumptions used in the accounting for these plans include the discount rate, expected return on plan assets and rate of increase in employee compensation levels. Assumptions are determined based on Company data and appropriate market indicators, and are evaluated each year as of the plans' measurement date. A change in any of these assumptions would have an effect on net periodic pension costs reported in the consolidated financial statements. Lower market interest rates and plan asset returns have resulted in declines in pension plan asset performance and funded status and higher pension expense. The discount rate used in determining pension expense in 2003 is 6.75%. Income Taxes The recorded future tax benefit arising from net deductible temporary differences and tax carryforwards is approximately $11.0 million at March 31, 2003. Management believes that our earnings during the periods when the temporary differences become deductible will be sufficient to realize the related future income tax benefits. 24

In assessing the need for a valuation allowance, we estimate future taxable income, considering the feasibility of ongoing tax planning strategies and the realizability of tax loss carryforwards. Valuation allowances related to deferred tax assets can be impacted by changes to tax laws, changes to statutory tax rates and future taxable income levels. In the event we were to determine that we would not be able to realize all or a portion of our deferred tax assets in the future, we would reduce such amounts through a charge to income in the period that such determination was made. Results of Operations Three months ended March 31, 2003 compared to three months ended March 31, 2002 The following table presents, as a percentage of net sales, certain categories included in our unaudited consolidated statements of income for the periods indicated: Three Months Ended March 31, 2002 2003 ------- ------- (unaudited) Net sales.............................................................. 100.0% 100.0% Cost of sales.......................................................... 47.8 47.8 ------- ------- Gross profit...................................................... 52.2 52.2 Selling and administrative............................................. 30.4 31.5 Research and development............................................... 3.4 3.1 In-process R & D write-off............................................. -- 6.7 Other expense (income)................................................. -- (6.4) ------- ------- Income from operations............................................ 18.4 17.3 Interest expense....................................................... 5.9 4.8 ------- ------- Income before income taxes........................................ 12.5 12.5 Provision for income taxes............................................. 4.5 6.9 ------- ------- Net income........................................................ 8.0% 5.6% ======= ======= Sales for the quarter ended March 31, 2003 were $118.0 million, an increase of 4.2% compared to sales of $113.2 million in the same quarter a year ago. Favorable changes in foreign currency exchange rates accounted for 2.2% of our sales growth. o Sales in our orthopedic businesses increased 4.3% to $72.7 million from $69.7 million in the comparable quarter last year. o Arthroscopy sales, which represented approximately 57.4% of total first quarter 2003 orthopedic revenues, grew 1.0% to $41.7 million from $41.3 million in the same period a year ago as sales of imaging systems improved while sales of procedure specific and fluid management products were slightly less than the same period a year ago. o Powered surgical instrument sales, which represented approximately 42.6% of orthopedic revenues, increased 9.2% to $31.0 million from $28.4 million in the same quarter last year on the strength of our PowerPro(R) battery powered instrument product line. o Patient care sales for the three months ended March 31, 2003 were $17.3 million, flat when compared to the same period a year ago as increases in sales of our automatic defibrillator pad and certain other products were offset by decreases in the suction instrument product lines. 25

o Electrosurgery sales for the three months ended March 31, 2003 were $16.8 million, flat when compared to the first quarter of last year, as declines in sales of electrosurgical generators offset gains in sales of disposables when compared with the same period a year ago. o Sales of endoscopy products increased 13.8% to $10.7 million in the three months ended March 31, 2003 from $9.4 million in the same period a year ago as a result of the CORE acquisition. Cost of sales increased to $56.4 million in the first quarter 2003 as compared to $54.1 million in the same quarter a year ago, primarily as a result of the increased sales volumes described above while gross margin percentage remained at 52.2% in the first quarter of 2003, the same as in the first quarter of 2002. Included in cost of sales during the quarter ended March 31, 2003 were approximately $.4 million in acquisition-related costs. Selling and administrative expense increased to $37.1 million in the first quarter of 2003 as compared to $34.5 million in the first quarter of 2002. As a percentage of sales, selling and administrative expense totaled 31.5% in the first quarter of 2003 compared to 30.4% in the first quarter of 2002. The increase in selling and administrative expense as a percentage of sales is due principally to increased marketing costs associated with recently launched product lines including the integrated operating room systems product lines, PowerPro(R), and new electrosurgical generators. Research and development expense decreased to $3.7 million in the first quarter of 2003 as compared to $3.8 million in the first quarter of 2002. As a percentage of sales, research and development expense also decreased to 3.1% in the current quarter compared to 3.4% in the same quarter a year ago but remains within the range of our historical percentages. As discussed in Note 6 to the consolidated condensed financial statements, we wrote off purchased in-process research and development assets in connection with the Bionx acquisition of $7.9 million in the first quarter of 2003. As discussed in Note 7 to the consolidated condensed financial statements, other expense (income) is comprised of a net gain on settlement of a contractual dispute of $9.0 million offset by other acquisition-related costs of $1.3 million and the loss of $.2 million on the early extinguishment of debt. There was no other expense (income) in the comparable quarter in 2002. Interest expense in the first quarter of 2003 was $5.5 million compared to $6.6 million in the first quarter of 2002. The decrease in interest expense is primarily a result of lower total borrowings outstanding during the current quarter as compared to the same period a year ago, as borrowings have declined to $285.3 million at March 31, 2003 as compared to $326.0 million at March 31, 2002. Additionally, the weighted average interest rates on our borrowings has declined to 5.91% at March 31, 2003 as compared to 6.25% at March 31, 2002. Provision for income taxes has been recorded at an effective rate of 55% for the first quarter 2003 and 36% for the first quarter 2002. The effective rate of 55% for the first quarter 2003 is substantially higher than the 36% which we have experienced historically as a result of the non-deductibility for income tax purposes of the $7.9 million in-process research and development write-off recorded in the first quarter 2003 in conjunction with the Bionx acquisition. A reconciliation of the United States statutory income tax rate of 35% to our historical effective tax rate of 36% (excluding the effect of the in-process research and development write-off) is included in Note 7 to the Company's financial statements for the year ended December 31, 2002 included in our Annual Report to the Securities and Exchange Commission on Form 10-K. 26

Liquidity and Capital Resources Cash generated from our operations and borrowings under our revolving credit facility have traditionally provided the working capital for our operations, debt service under our credit facility and the funding of our capital expenditures. In addition, we have used term borrowings, including: o borrowings under our senior credit agreement; o Senior Subordinated Notes issued to refinance borrowings under our senior credit agreement, in the case of the acquisition of Linvatec Corporation in 1997; o borrowings under separate loan facilities, in the case of real property acquisitions, to finance our acquisitions. The senior credit agreement consists of a $100 million term loan and a $100 million revolving credit facility of which $99.5 million and $36.0 million, respectively, was outstanding at March 31, 2003. The weighted average interest rates at March 31, 2003 on the term loan and revolving credit facility were 4.09% and 5.75%, respectively. The Senior Subordinated Notes (the "Notes") are in aggregate principal amount outstanding at March 31, 2003, of $127.4 million, have a maturity date of March 15, 2008 and bear interest at 9.0% per annum which is payable semi-annually. The Notes are redeemable for cash at anytime on or after March 15, 2003, at our option, in whole or in part, at the redemption prices set forth therein, plus accrued and unpaid interest to the date of redemption. During the quarter ended March 31, 2003, we purchased $2.6 million of our Notes at 104.5% and recorded expense of $.2 million in premium and unamortized deferred financing costs as discussed in Note 7 to the consolidated condensed financial statements. On March 12, 2003, we served notice to the trustee for the Notes that we would redeem $15.0 million par value of the Notes, on May 1, 2003, at the redemption price of 104.5%, for a total redemption price of $15.7 million, plus accrued and unpaid interest. We redeemed those Notes on May 1, 2003 through borrowings under our revolving credit facility. The premium paid on the Notes will be recorded as a charge to operating income in the second quarter of 2003. Although the outstanding Notes do not mature until 2008, we continue to review alternatives for redeeming the remaining outstanding Notes, including the addition of a term loan tranche under the senior credit agreement to redeem all outstanding Notes at the applicable redemption price. We used term loans to purchase the property in Largo, Florida utilized by our Linvatec subsidiary. The term loans consist of a Class A note bearing interest at 7.50%, a Class C note bearing interest at 8.25% and a seller-financed note bearing interest at 6.50%. The principal balances outstanding on the Class A note, Class C note and seller-financed note aggregate $10.7 million, $7.1 million and $3.9 million, respectively, at March 31, 2003. These loans are secured by our Largo, Florida property. We have a five-year accounts receivable sales agreement pursuant to which we and certain of our subsidiaries sell on an ongoing basis certain accounts receivable to CONMED Receivables Corporation, a wholly-owned special-purpose subsidiary of CONMED Corporation. CRC may in turn sell up to an aggregate $50.0 million undivided percentage ownership interest in such receivables to a commercial paper conduit (the "conduit purchaser"). As of December 31, 2002 and March 31, 2003, the undivided percentage ownership interest in receivables sold by CRC to the conduit purchaser aggregated $37.0 million, which has been accounted for as a sale and reflected in the balance sheet as a reduction in accounts receivable. Our net working capital position was $144.3 million at March 31, 2003. Net cash provided by operations increased to $20.5 million in the three months ended March 31, 27

2003 compared to $12.4 million for the same period a year ago, principally as a result of the $9.0 million gain on the settlement of a contractual dispute discussed in Note 7 to the consolidated financial statements. Net cash provided by operations in the first quarter of 2003 was positively impacted by depreciation, amortization, the non-cash write-off of purchased in-process research and development and increases in income taxes payable and deferred income taxes and negatively impacted primarily by increases in inventory and decreases in accounts payable, accrued compensation and accrued interest. The increase in inventory is a result of the Bionx acquisition discussed in Note 6 to the consolidated condensed financial statements. The increases in income taxes payable and deferred income taxes and decreases in accounts payable, accrued compensation and accrued interest are primarily related to the timing of the payment of these liabilities. Capital expenditures in the three months ended March 31, 2003 were $1.7 million compared to $3.2 million in the same period a year ago. These capital expenditures represent the ongoing capital investment requirements of our business and are expected to continue at the rate of approximately $12.0 to $14.0 million annually. Net cash used by investing activities in the three months ended March 31, 2003 also included $48.2 million in payments related to business acquisitions, net of cash acquired, of which $46.5 million related to the Bionx acquisition and the remainder related to the CORE acquisition as discussed in Note 6 to the consolidated condensed financial statements. Financing activities in the three months ended March 31, 2003 consisted of payments on our debt of $3.1 million and borrowings on our revolving credit facility of $31.0 million in order to finance the Bionx acquisition. Proceeds from the exercise of stock options in the three months ended March 31, 2003 totaled $.8 million. Management believes that cash generated from operations, our current cash resources and funds available under our new senior credit agreement will provide sufficient liquidity to ensure continued working capital for operations, debt service and funding of capital expenditures in the foreseeable future. Contractual Obligations There were no capital lease obligations or unconditional purchase obligations as of March 31, 2003. The following table summarizes our contractual obligations related to operating leases and long-term debt as of March 31, 2003: (Amounts in thousands) 2003 2004 2005 2006 2007 Thereafter ---- ---- ---- ---- ---- ---------- Long-term debt............. $ 2,072 $ 2,554 $ 2,741 $ 2,943 $133,914 $141,112 Operating lease obligations.............. 1,783 1,589 1,310 1,238 1,259 3,173 ------- ------- ------- ------- -------- -------- Total contractual cash obligations......... $ 3,855 $ 4,143 $ 4,051 $ 4,182 $135,174 $144,285 ======= ======= ======= ======= ======== ======== 28

Item 3. Quantitative and Qualitative Disclosures About Market Risk There has been no significant change in our exposures to market risk during the three months ended March 31, 2003. For a detailed discussion of market risk, see our Annual Report on Form 10K for the year-ended December 31, 2002, Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk. Item 4. Controls and Procedures Within the 90-day period prior to the filing of this report, an evaluation was carried out under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-14(c) under the Securities Exchange Act of 1934). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were effective. No significant changes were made in our internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, provided, however, that, as a result of the required restatement, procedures have been implemented to ensure in the future, a preliminary allocation of purchase price will be made in the quarter in which the applicable acquisition is made. PART II OTHER INFORMATION Item 6. Exhibits and Reports on Form 8-K List of Exhibits Exhibit No. Description of Exhibit - ----------- ---------------------- 31.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Reports on Form 8-K On April 29, 2003, the Company filed a Report on Form 8-K furnishing as Exhibit 99.1 under Item 7, an April 24, 2003 press release announcing first quarter results. On May 1, 2003, the Company filed a Report on Form 8-K under Item 5, a supplement to the discussion under Liquidity and Capital Resources included in our Form 10-K for the year-ended December 31, 2002. 29

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CONMED CORPORATION (Registrant) Date: August 11, 2003 /s/ Robert D. Shallish, Jr. --------------------------------- Robert D. Shallish, Jr. Vice President - Finance (Principal Financial Officer) 30

Exhibit Index Sequential Page Exhibit Number - ------- ------ 31.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 E-1 31.2 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 E-2 32.1 Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 E-3 31

                                                                    Exhibit 31.1

                                  CERTIFICATION

I, Eugene R. Corasanti, certify that:

1.    I have reviewed this quarterly report on Form 10-Q/A of CONMED
      Corporation;

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      the registrant as of, and for, the periods presented in this report;

4.    The registrant's other certifying officer(s) and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant
      and have:

      a)    Designed such disclosure controls and procedures, or caused such
            disclosure controls and procedures to be designed under our
            supervision, to ensure that material information relating to the
            registrant, including its consolidated subsidiaries, is made known
            to us by others within those entities, particularly during the
            period in which this report is being prepared;

      b)    Evaluated the effectiveness of the registrant's disclosure controls
            and procedures and presented in this report our conclusions about
            the effectiveness of the disclosure controls and procedures, as of
            the end of the period covered by this report based on such
            evaluation; and

      c)    Disclosed in this report any change in the registrant's internal
            control over financial reporting that occurred during the
            registrant's most recent fiscal quarter (the registrant's fourth
            fiscal quarter in the case of an annual report) that has materially
            affected, or is reasonably likely to materially affect, the
            registrant's internal control over financial reporting; and

5.    The registrant's other certifying officer(s) and I have disclosed, based
      on our most recent evaluation of internal control over financial
      reporting, to the registrant's auditors and the audit committee of the
      registrant's board of directors (or persons performing the equivalent
      function):

      a)    All significant deficiencies and material weaknesses in the design
            or operation of internal control over financial reporting which are
            reasonably likely to adversely affect the registrant's ability to
            record, process, summarize and report financial information; and

      b)    Any fraud, whether or not material, that involves management or
            other employees who have a significant role in the registrant's
            internal control over financial reporting.

August 11, 2003


                                           /s/ Eugene R. Corasanti
                                           -----------------------
                                           Eugene R. Corasanti
                                           Chairman and Chief Executive Officer


                                      E-1

                                                                    Exhibit 31.2

                                  CERTIFICATION

I, Robert D. Shallish, certify that:

1.    I have reviewed this quarterly report on Form 10-Q/A of CONMED
      Corporation;

2.    Based on my knowledge, this quarterly report does not contain any untrue
      statement of a material fact or omit to state a material fact necessary to
      make the statements made, in light of the circumstances under which such
      statements were made, not misleading with respect to the period covered by
      this report;

3.    Based on my knowledge, the financial statements, and other financial
      information included in this report, fairly present in all material
      respects the financial condition, results of operations and cash flows of
      the registrant as of, and for, the periods presented in this report;

4.    The registrant's other certifying officer(s) and I are responsible for
      establishing and maintaining disclosure controls and procedures (as
      defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant
      and have:

      a)    Designed such disclosure controls and procedures, or caused such
            disclosure controls and procedures to be designed under our
            supervision, to ensure that material information relating to the
            registrant, including its consolidated subsidiaries, is made known
            to us by others within those entities, particularly during the
            period in which this report is being prepared;

      b)    Evaluated the effectiveness of the registrant's disclosure controls
            and procedures and presented in this report our conclusions about
            the effectiveness of the disclosure controls and procedures, as of
            the end of the period covered by this report based on such
            evaluation; and

      c)    Disclosed in this report any change in the registrant's internal
            control over financial reporting that occurred during the
            registrant's most recent fiscal quarter (the registrant's fourth
            fiscal quarter in the case of an annual report) that has materially
            affected, or is reasonably likely to materially affect, the
            registrant's internal control over financial reporting; and

5.    The registrant's other certifying officer(s) and I have disclosed, based
      on our most recent evaluation of internal control over financial
      reporting, to the registrant's auditors and the audit committee of the
      registrant's board of directors (or persons performing the equivalent
      function):

      a)    All significant deficiencies and material weaknesses in the design
            or operation of internal control over financial reporting which are
            reasonably likely to adversely affect the registrant's ability to
            record, process, summarize and report financial information; and

      b)    Any fraud, whether or not material, that involves management or
            other employees who have a significant role in the registrant's
            internal control over financial reporting.

August 11, 2003


                                                 /s/ Robert D. Shallish Jr.
                                                 --------------------------
                                                 Robert D. Shallish, Jr.
                                                 Vice President - Finance and
                                                 Chief Financial Officer


                                      E-2

                                                                    Exhibit 32.1

                           Section 1350 Certifications
            Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
        (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18,
                               United States Code)

      Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)
and (b) of section 1350, chapter 63 of title 18, United States Code), each of
the undersigned officers of CONMED Corporation, a New York corporation (the
"Corporation"), does hereby certify that:

      The Quarterly Report on Form 10-Q/A for the quarter ended March 31, 2003
(the "Form 10-Q/A") of the Corporation fully complies with the requirements of
section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information
contained in the Form 10-Q/A fairly presents, in all material respects, the
financial condition and results of operations of the Corporation.


Date: August 11, 2003         /s/ Eugene R. Corasanti
                              -----------------------
                              Eugene R. Corasanti
                              Chairman and Chief Executive Officer


Date: August 11, 2003         /s/ Robert D. Shallish, Jr.
                              --------------------------
                              Robert D. Shallish, Jr.
                              Vice President-Finance and Chief Financial Officer

The foregoing certification is being furnished as an exhibit to the Form 10-Q/A
pursuant to Item 601(b)(32) of Regulation S-K and section 906 of the
Sarbanes-Oxley Act of 2002 (subsection (a) and (b) of section 1350, chapter 63
of title 18, United States Code) and, accordingly, is not being filed as part of
the Form 10-Q/A.


                                      E-3